This trial features two experimental immunotherapy drugs, NIS793 and PDR001. These drugs work by enhancing or changing the way that the immune system responds to cancerous cells.
PDR001 targets a molecule called PD-1, similar to an already approved immunotherapy called pembrolizumab (Keytruda®). This allows the immune system to more effectively target and destroy cancer cells.
Meanwhile, NIS793 works by blocking a new potential cancer-target called TGF–β. Research has shown that the loss of this factor may prevent cancerous cells from growing, dividing, and spreading.
Patients enrolling on this study will be randomly assigned to one of two groups:
- NIS793 Alone
- NIS793 + PDR001
This study is specifically designed for patients with advanced kidney cancer who have completed standard therapy and whose cancer has continued to grow despite treatment.
- All subtypes eligible
- Cancer has spread or cannot be removed by surgery
- Must be able and willing to undergo a tumour biopsy
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentreNovartis Investigative Site||Principal Investigator||LocationToronto, ON||Trial StatusRecruiting|